Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Business Operations | June 09, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date June 09, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,398 |
Ending reported balance
After 2023-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-09 · Grant · Acquired 24,616 · Balance 125,167 F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Row 2 · 2023-06-09 · Grant · Acquired 49,231 · Balance 174,398 F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-06-08 | Direct | 161,906 |
Reported balance
After 2023-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-09 · Grant · Acquired 49,231 · Balance 161,906 F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 23:40 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,019 | $57.92 | $59,022.31 |
DisclosureSEC source: 0001567619-19-006067 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,694 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $57.52 to $58.49, inclusive. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 409 | $57.98 | $23,713.82 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,525 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,321 | $61.01 Strike: $61.01 | $1,239,784.21 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,321 Underlying: Common Stock · 20,321 shares Expires 2026-02-25 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,934 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,853 F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 481 | $61.01 | $29,345.81 |
DisclosureSEC source: 0001567619-19-005679 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,772 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,168 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,168 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,168 | $64.50 | $397,836.00 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,168 | $25.62 | $158,024.16 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,011 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · derivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,168 Underlying: Common Stock · 2,011 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,011 | $63.50 | $127,698.50 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 2,011 | $25.62 | $51,521.82 |
DisclosureSEC source: 0001567619-18-005093 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 21:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Options (Right to Buy) · Derivative | 314 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-004358 · doc1.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,179 Underlying: Common Stock · 314 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 21:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 314 | $61.50 | $19,311.00 |
DisclosureSEC source: 0001567619-18-004358 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 21:06 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 314 | $25.62 | $8,044.68 |
DisclosureSEC source: 0001567619-18-004358 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 17, 2018 Filed Oct 24, 2018 20:25 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 314 | $63.50 | $19,939.00 |
DisclosureSEC source: 0001567619-18-004474 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: This form 4/A is being filed to amend the sales price of the shares. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,840 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · derivative · entry 13 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,493 Underlying: Common Stock · 3,840 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F5 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · derivative · entry 12 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,333 Underlying: Common Stock · 6,165 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F5 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,840 | $63.50 | $243,840.00 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 9 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,840 | $25.62 | $98,380.80 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 8 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,165 | $61.50 | $379,147.50 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 7 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,165 | $25.62 | $157,947.30 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · derivative · entry 11 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Underlying: Common Stock · 6,165 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F5 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,165 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · derivative · entry 10 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,663 Underlying: Common Stock · 6,165 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F5 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 661 | $60.67 | $40,102.87 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,165 | $60.03 | $370,080.63 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,914 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.67, inclusive. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,165 | $25.62 | $157,947.30 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 6,165 | $60.15 | $370,854.96 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,914 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.31 to $60.67, inclusive. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,165 | $25.62 | $157,947.30 |
DisclosureSEC source: 0001567619-18-004223 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,842 | $52.82 | $308,574.44 |
DisclosureSEC source: 0001140361-18-013317 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,914 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.50 to $53.16, inclusive. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:57 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 974 | $51.84 | $50,492.16 |
DisclosureSEC source: 0001140361-18-013317 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,756 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,573 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,573 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F3 · derivative.exercise_date: The option vested in three equal installments in March 2012, March 2013 and March 2014. Each option represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,843 | $50.43 | $143,372.49 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,730 F1 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting persons exercise price for the reported stock option exercise. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 22:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 6,573 | $22.03 | $144,803.19 |
DisclosureSEC source: 0001140361-18-012878 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,898 | $49.50 | $93,951.00 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 5 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F5 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 811 | $49.97 | $40,525.67 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,898 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (right to buy · Derivative | 20,145 | $49.64 Strike: $49.64 | $999,997.80 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · derivative · entry 6 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,145 Underlying: Common Stock · 20,145 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 409 | $49.64 | $20,302.76 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,709 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,118 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,082 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:52 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,885 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-17-036981 · doc1.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,885 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:52 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,885 | $39.50 | $311,457.50 |
DisclosureSEC source: 0001140361-17-036981 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,046 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| September 27, 2017 Filed Sep 29, 2017 20:52 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,885 | $22.03 | $173,706.55 |
DisclosureSEC source: 0001140361-17-036981 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 19:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,885 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001140361-17-035190 · doc1.xml · derivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,885 Underlying: Common Stock · 7,885 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 19:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,885 | $37.06 | $292,242.54 |
DisclosureSEC source: 0001140361-17-035190 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,046 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.87 to $37.59, inclusive. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 19:56 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,885 | $22.03 | $173,706.55 |
DisclosureSEC source: 0001140361-17-035190 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Business Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 11,419 | $28.62 | $326,808.35 |
DisclosureSEC source: 0001140361-17-014647 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,046 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.19, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 15:28 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GiftCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-012231 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,465 F1 · kind: This transaction involved a gift of issuer common stock by the reporting person to a charitable gift fund. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 02:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,624 | $31.05 | $50,425.20 |
DisclosureSEC source: 0001140361-17-011684 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,265 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:38 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,076 | $30.98 | $33,334.48 |
DisclosureSEC source: 0001140361-17-011684 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,889 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.